Antibiotic treatment outcomes in community-acquired pneumonia

There was no difference in survival among the three treatment groups.Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between β-lactam,β-lactam and macrolide combination, and fluoroquinolone regimens.

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear.This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with communityacquired pneumonia in nonintensive care unit (ICU) wards and treated with a β-lactam, β-lactam and macrolide combination, or afluoroquinolone.Materials and methods: This prospective cohort study was performed using standardized web-based database sheets from January 2009to September 2013 in nine tertiary care hospitals in Turkey.Results: Six hundred and twenty-one consecutive patients were enrolled.

📊

Temel Bulgular & Veri:A pathogen was identified in 78 (12.6%) patients.

💡

Sonuç & Katkı:There was no difference in survival among the three treatment groups.Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between β-lactam,β-lactam and macrolide combination, and fluoroquinolone regimens.

🔬Tür:Araştırma Makalesi

📍Kapsam:2013 Verileri

⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear.This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with communityacquired pneumonia in nonintensive care unit (ICU) wards and treated with a β-lactam, β-lactam and macrolide combination, or afluoroquinolone.Materials and methods: This prospective cohort study was performed using standardized web-based database sheets from January 2009to September 2013 in nine tertiary care hospitals in Turkey.Results: Six hundred and twenty-one consecutive patients were enrolled. A pathogen was identified in 78 (12.6%) patients. The mostfrequently isolated bacteria were S. pneumoniae (21.8%) and P. aeruginosa (19.2%). The clinical cure rate and length of stay were notdifferent among patients treated with β-lactam, β-lactam and macrolide combination, and fluoroquinolone. Forty-seven patients (9.2%)died during the hospitalization period. There was no difference in survival among the three treatment groups.Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between β-lactam,β-lactam and macrolide combination, and fluoroquinolone regimens.

🔖

Bu Makaleye Atıf Yap

TAŞBAKAN, S., COŞKUN, A. Ş., BİLGE, U., SAYINER, A., ÇİLLİ, A., KILIÇ, Ö., HAVLUCU, Y., TOKGÖZ, F., SAMUR, A. A., WATERER, G. W., KILINÇ, O., HAZAR, A., ÇELENK, B. (2022). Antibiotic treatment outcomes in community-acquired pneumonia. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 4, 730–736. https://ajindex.com/articles/610381

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

Van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, Boersma WG. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672-678.
Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: 1-55.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: 27-72.
Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infec 2011; 17: 1-59. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM et al. CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. New Engl J Med 2015; 372: 1312-1323.
Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Db Syst Rev 2012; 9: CD004418. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012; 55: 371-380.
Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014; 42: 420-432.
Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of communityacquired pneumonia in adults: a systematic review and metaanalysis. J Antimicrob Chemoth 2014; 69: 1441-1446.
Rodrigo C, McKeever TM, Woodhead M, Lim WS. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2013; 68: 493- 495. Garin N, Genné D, Carballo S, Chuard C